MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, MREO had -$30,664K decrease in cash & cash equivalents over the period. -$30,991K in free cash flow.

Cash Flow Overview

Change in Cash
-$30,664K
Free Cash flow
-$30,991K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Share-based compensation
    • Foreign currency transaction los...
    • Research and development incenti...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Accrued expenses and other liabi...
    • Accounts payable
    • Others

Cash Flow
2025-12-31
Net loss
-41,878
Share-based compensation
7,598
Depreciation
157
Amortization of intangible assets
465
Amortization of operating lease right-of-use assets
527
Change in fair value of warrants
-805
Non-cash interest income
104
Non-cash interest expense
228
Foreign currency transaction loss/(gain)
-6,344
Other income
300
Non-cash consideration, milestone payment
0
Prepaid expenses and other current assets
84
Research and development incentives receivable
-1,396
Accounts payable
-1,378
Accrued expenses and other liabilities
-2,394
Operating lease liabilities
-743
Net cash used in operating activities
-30,971
Purchase of intangible assets
300
Purchase of property and equipment
20
Proceeds from out-licensing
300
Net cash used in investing activities
-20
Proceeds from exercise of warrants
487
Proceeds from issuance of ordinary shares
39
Transaction costs on issuance of ordinary shares
199
Net cash provided by financing activities
327
(decrease)/increase in cash and cash equivalents
-30,664
Cash and cash equivalents at january 1
69,802
Effect of exchange rate changes
1,854
Cash and cash equivalents at december 31
40,992
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from exercise ofwarrants$487K Proceeds from issuance ofordinary shares$39K Net cash provided byfinancing activities$327K Canceled cashflow$199K (decrease)/increase in cash and cashequivalents-$30,664K Canceled cashflow$327K Share-based compensation$7,598K Foreign currencytransaction loss/(gain)-$6,344K Research and developmentincentives receivable-$1,396K Amortization of operatinglease right-of-use...$527K Amortization of intangibleassets$465K Non-cash interestexpense$228K Depreciation$157K Proceeds fromout-licensing$300K Transaction costs onissuance of ordinary...$199K Net cash used inoperating activities-$30,971K Canceled cashflow$16,715K Net cash used ininvesting activities-$20K Canceled cashflow$300K Net loss-$41,878K Accrued expenses andother liabilities-$2,394K Accounts payable-$1,378K Change in fair value ofwarrants-$805K Operating leaseliabilities-$743K Other income$300K Non-cash interest income$104K Prepaid expenses andother current assets$84K Purchase of intangibleassets$300K Purchase of property andequipment$20K

Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group plc (MREO)